摘要
目的探讨依折麦布联合增强型体外反搏对不稳定型心绞痛患者的血管内皮功能、脂代谢、心功能及心绞痛发作情况的影响。方法选取邢台市中心医院(原邢台市第三医院)于2023年2月至2024年3月收治的不稳定型心绞痛患者100例,根据随机信封法分为对照组(常规治疗+依折麦布治疗,50例)和观察组(常规治疗+依折麦布联合增强型体外反搏治疗,50例)。比较两组患者治疗前和治疗2周后血清内皮素1、血栓素B2、血管内皮生长因子等血管内皮功能指标,血清甘油三酯、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇等脂代谢指标,左室射血分数、每搏输出量等心功能指标,以及心绞痛发作情况和西雅图心绞痛量表评分。结果治疗2周后观察组患者的内皮素1水平[(56.03±5.04)ng·L^(-1)]、血栓素B2水平[(127.56±10.24)ng·L^(-1)]、甘油三酯水平[(1.82±0.35)mmol·L^(-1)]、总胆固醇水平[(3.40±0.75)mmol·L^(-1)]、低密度脂蛋白胆固醇水平[(2.13±0.36)mmol·L^(-1)]、心绞痛发作频率[(6.24±1.55)次/周]和发作时间[(3.41±1.08)min/次]低于对照组[(61.44±5.49)ng·L^(-1)、(141.88±9.87)ng·L^(-1)、(2.01±0.42)mmol·L^(-1)、(4.21±0.88)mmol·L^(-1)、(2.40±0.42)mmol·L^(-1)、(8.51±1.79)次/周、(5.20±1.17)min/次](t=5.133、7.120、2.457、4.954、3.451、6.779、7.949,均P<0.05),血管内皮生长因子水平[(70.68±6.22)ng·L^(-1)]、高密度脂蛋白胆固醇水平[(1.63±0.21)mmol·L^(-1)]、左室射血分数(56.27±5.12)%、每搏输出量[(73.44±5.77)mL·min^(-1)]和西雅图心绞痛量表评分[(89.39±8.23)分]高于对照组[(64.70±5.44)ng·L^(-1)、(1.42±0.22)mmol·L^(-1)、(50.75±5.53)%、(67.26±5.47)mL·min^(-1)、(83.52±7.82)分](t=5.117、4.882、5.179、5.496、3.656,均P<0.05)。结论依折麦布联合增强型体外反搏能够有效改善不稳定型心绞痛患者的血管内皮功能、脂代谢和心功能,减轻心绞痛发作,提升生活质量,具有较好的临床应用价值。
Objective To investigate the effects of ezetimibe combined with enhanced external counterpulsation on the vascular endothelial function,lipid metabolism,cardiac function,and angina attacks in patients with unstable angina.Methods A total of 100 patients with unstable angina who were admitted to the Xingtai Central Hospital(Former Xingtai Third Hospital)from February 2023 to March 2024 were selected and randomly divided into the control group(conventional treatment pluse zetimibe,50 cases)and the observation group(conventional treatment pluse zetimibe combined with enhanced external counterpulsation,50 cases)using the random envelope method.The vascular endothelial function indicators(serum endothelin-1,thromboxane B2,vascular endothelial growth factor,etc.),the lipid metabolism indicators(serum triglycerides,total cholesterol,low-density lipoprotein cholesterol,high-density lipoprotein cholesterol,etc.),cardiac function indicators(left ventricular ejection fraction,stroke volume,etc.),and the condition of angina attacks and Seattle Angina Questionnaire scores were compared between the two groups before treatment and 2 weeks after treatment.Results After 2 weeks of treatment,the levels of endothelin-1((56.03±5.04)ng·L^(-1)),thromboxane B2((127.56±10.24)ng·L^(-1)),triglycerides((1.82±0.35)mmol·L^(-1)),total cholesterol((3.40±0.75)mmol·L^(-1)),low-density lipoprotein cholesterol((2.13±0.36)mmol·L^(-1)),the frequency of angina attacks((6.24±1.55)times·week^(-1))),and the duration of each attack((3.41±1.08 min·time^(-1))in the observation group were lower than those in the control group(endothelin-1:(61.44±5.49)ng·L^(-1),thromboxane B2:(141.88±9.87)ng·L^(-1),triglycerides:(2.01±0.42)mmol·L^(-1),total cholesterol:(4.21±0.88)mmol·L^(-1),low-density lipoprotein cholesterol:(2.40±0.42)mmol·L^(-1),frequency of angina attacks:(8.51±1.79)times·week^(-1),duration of each attack:(5.20±1.17)min·time^(-1))(t=5.133,7.120,2.457,4.954,3.451,6.779,7.949,all P<0.05).The vascular endothelial growth factor level((70.68±6.22)ng·L^(-1)),high-density lipoprotein cholesterol level((1.63±0.21)mmol·L^(-1)),left ventricular ejection fraction((56.27±5.12)%),stroke volume((73.44±5.77)mL·min^(-1)),and Seattle Angina Questionnaire score((89.39±8.23)points)in the observation group were higher than those in the control group(vascular endothelial growth factor:(64.70±5.44)ng·L^(-1),high-density lipoprotein cholesterol:(1.42±0.22)mmol·L^(-1),left ventricular ejection fraction:(50.75±5.53)%,stroke volume:(67.26±5.47)mL·min^(-1),Seattle Angina Questionnaire score:(83.52±7.82)points)(t=5.117,4.882,5.179,5.496,3.656,all P<0.05).Conclusion Ezetimibe combined with enhanced external counterpulsation can effectively improve the vascular endothelial function,lipid metabolism,and cardiac function of patients with unstable angina,alleviate angina attacks,and improve the quality of life,thus having good clinical application value.
作者
张丽
李华伟
卫瑞芳
王宏斌
Zhang Li;Li Huawei;Wei Ruifang;Wang Hongbin(Fourth Department of Cardiology,Xingtai Central Hospital(Former Xingtai Third Hospital),Xingtai 054000,China)
出处
《中国药物应用与监测》
2025年第5期815-819,共5页
Chinese Journal of Drug Application and Monitoring
基金
邢台市重点研发计划自筹项目(2022ZC117)。
关键词
心绞痛
依折麦布
增强型体外反搏
血管内皮功能
脂代谢
Unstable angina
Ezetimibe
Enhanced external counterpulsation
Vascular endothelial function
Lipid metabolism
